WallStSmart

AptarGroup Inc (ATR)vsAstraZeneca PLC (AZN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AstraZeneca PLC generates 1460% more annual revenue ($61.37B vs $3.93B). AZN leads profitability with a 17.0% profit margin vs 9.2%. AZN appears more attractively valued with a PEG of 1.47. AZN earns a higher WallStSmart Score of 60/100 (C+).

ATR

Hold

46

out of 100

Grade: D+

Growth: 4.0Profit: 6.0Value: 4.0Quality: 6.0
Piotroski: 3/9Altman Z: 2.57

AZN

Buy

60

out of 100

Grade: C+

Growth: 5.3Profit: 8.0Value: 6.0Quality: 5.0
Piotroski: 6/9Altman Z: 1.48
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ATRSignificantly Overvalued (-41.6%)

Margin of Safety

-41.6%

Fair Value

$98.87

Current Price

$135.42

$36.55 premium

UndervaluedFair: $98.87Overvalued
AZNUndervalued (+13.9%)

Margin of Safety

+13.9%

Fair Value

$196.93

Current Price

$161.42

$35.51 discount

UndervaluedFair: $196.93Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ATR0 strengths · Avg: 0/10

No standout strengths identified

AZN4 strengths · Avg: 8.8/10
Market CapQuality
$263.09B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
20.7%9/10

Every $100 of equity generates 21 in profit

Operating MarginProfitability
23.5%8/10

Strong operational efficiency at 23.5%

Free Cash FlowQuality
$2.13B8/10

Generating 2.1B in free cash flow

Areas to Watch

ATR3 concerns · Avg: 3.0/10
PEG RatioValuation
2.414/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EPS GrowthGrowth
-18.6%2/10

Earnings declined 18.6%

AZN3 concerns · Avg: 3.3/10
P/E RatioValuation
25.6x4/10

Moderate valuation

EPS GrowthGrowth
2.5%4/10

2.5% earnings growth

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : ATR

ATR has a balanced fundamental profile.

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.47 suggests the stock is reasonably priced for its growth.

Bear Case : ATR

The primary concerns for ATR are PEG Ratio, Piotroski F-Score, EPS Growth.

Bear Case : AZN

The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.

Key Dynamics to Monitor

ATR profiles as a value stock while AZN is a mature play — different risk/reward profiles.

ATR carries more volatility with a beta of 0.39 — expect wider price swings.

AZN is growing revenue faster at 6.4% — sustainability is the question.

AZN generates stronger free cash flow (2.1B), providing more financial flexibility.

Bottom Line

AZN scores higher overall (60/100 vs 46/100), backed by strong 17.0% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AptarGroup Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

AptarGroup, Inc. offers a range of packaging, dispensing and sealing solutions primarily for the beauty, personal care, home care, prescription drug, consumer health care, injectables, and food and beverage markets. The company is headquartered in Crystal Lake, Illinois.

Visit Website →

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

Want to dig deeper into these stocks?